作者: Urszula L. McClurg , Mahsa Azizyan , Daniel T. Dransfield , Nivedita Namdev , Nay C.T.H. Chit
DOI: 10.18632/ONCOTARGET.25167
关键词:
摘要: Metastatic castration resistant prostate cancer is one of the main causes male associated deaths worldwide. Development resistance inevitable in patients treated with anti-androgen therapies. This highlights a need for novel therapeutic strategies that would be aimed upstream androgen receptor (AR). Here we report small molecule anti-androgen, galeterone targets USP12 and USP46, two highly homologous deubiquitinating enzymes control AR-AKT-MDM2-P53 signalling pathway. Consequently, effective multiple models including both castrate AR-negative cancer. However, have observed USP46 selectively regulate full length AR protein but not variants. first enzyme targeting as strategy treatment which show to multiple, currently incurable this disease.